An assessment of the diagnosis and management of XXXX in nursing homes.

@entity1 @entity1032 @entity303 @entity17826 @entity8124
OBJECTIVES: The purpose of this study was to evaluate the diagnosis and management of @entity303 in the nursing home setting through use of the @entity1032 ( @entity1032 ) and monitoring of acetylcholinesterase-inhibitor (ACHEI) therapy. DESIGN: Longitudinal cross-sectional study. SETTING: Long-term care facilities in Indiana. @entity1 : Residents in long-term care facilities were included. MAIN OUTCOME MEASURES: The number of residents with @entity1032 scores indicative of @entity303 , the presence of a @entity303 diagnosis, and receipt of ACHEI therapy. RESULTS: Data were collected on 782 residents. An @entity1032 score was available within the past 12 months in 456 (58.3%) of residents. The median @entity1032 score was 17 and ranged from 0 to 30 points. Out of the total population, @entity17826 therapy was prescribed in 165 (21.1%) residents. Seventy-five (29.2%) of the residents with mild-moderate @entity303 ( @entity1032 = 10-26) were prescribed ACHEI therapy. The most frequently prescribed ACHEI was @entity8124 10 mg/day prescribed in 98 (59.4%) of the residents receiving ACHEI therapy. Average length of ACHEI therapy was 9.0 months. CONCLUSION: @entity1032 scores were not available in a large proportion of this nursing home population (41.7%). Of those residents with an available @entity1032 score, a significant number of them had scores indicative of @entity303 . Despite having scores indicative of @entity303 , 182 (70.8%) residents were not receiving AChEI therapy. An assessment to determine why residents were not receiving therapy is needed. Opportunities exist to improve the screening, diagnosis, and treatment of @entity303 in the nursing home setting.
